Sign In
Search Icon
Menu Icon

COVID-19 Therapeutics Transition to Commercial Distribution: Frequently Asked Questions

November 14, 2023

Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program

This resource provides critical information on the transition of COVID-19 Therapeutics to the commercial market, including major milestones and dates, guidance on inventory disposal and management, data reporting requirements, and programs for uninsured and underinsured individuals.

Read the Guide

Frequently Asked Questions

Lagevrio: Lagevrio is not currently eligible for return as none of the USG-distributed Lagevrio has reached expiration; current expiration dates are February 2024 through February 2025. We are not aware of any upcoming shelf-life extensions for Lagevrio.

Paxlovid: Any expired product, once current expiration date is confirmed, should be returned as soon as expiration is reached. We are not aware of any upcoming shelf-life extensions for Paxlovid.

In addition, Paxlovid with an expiry of December 2023 or later (including non-expired Paxlovid) can be returned by December 31, 2023, to receive a replacement credit to USG inventory for use in the USG PAP operated by Pfizer. Questions regarding costs associated with return shipping should be directed to Pfizer. For all Paxlovid returns, visit Inmar (, email, or call 800-967-5952.

HHS is looking into ways to make commercially available COVID-19 treatment dispensing locations, including sites that continue to offer Test to Treat services and participating USG PAP sites operated through Pfizer, available on a locator tool. We will have more information on that in the coming weeks.

We ask that dispensing locations continue to provide information on where oral antivirals are located to enable everyone eligible to find the medicines they need.